Eli Lilly GLP-1 Pill Foundayo Wins Canadian Approval
Health Canada has authorized Eli Lilly’s daily weight-loss pill Foundayo, with pharmacy availability expected in January. The pill gives eligible adults another option alongside weekly injections, though dosing, costs and how quickly patients may see results can differ.

Health Canada authorized Eli Lilly’s daily GLP-1 pill Foundayo for weight loss and Type 2 diabetes on November 13. The decision gives eligible Canadians another option alongside weekly injections.
Eli Lilly spokesperson Ethan Pigott said the company expects the pills to reach pharmacies in January. Foundayo is already approved and available in the United States.
The Canadian authorization covers adults with obesity and people who are overweight with at least one related medical condition. Those conditions include high blood pressure and sleep apnea. Foundayo is also approved to help maintain weight loss.
Daily pills and weekly shots
Foundayo is taken once a day, while major injectable GLP-1 drugs such as Zepbound are administered weekly. The pill can be taken at any time, with or without food, according to Yale Medicine.
Dr. Hertzel Gerstein, a professor of medicine at McMaster University and Hamilton Health Sciences, said prescriptions often depend on what patients are most likely to follow.
“Some people would prefer the injection once a week and then forget about it. Some people will prefer the pill,” Gerstein said.
Foundayo contains orforglipron, a different active ingredient from the tirzepatide in Eli Lilly’s Zepbound injection. Foundayo starts at 0.8 milligrams and can rise to 17.2 milligrams. Zepbound starts at 2.5 milligrams and can reach 15 milligrams.
Another pill, Novo Nordisk’s Rybelsus, is already available in Canada. It is approved for managing Type 2 diabetes, not weight loss.
Novo Nordisk’s Wegovy pill is awaiting Health Canada approval. Its active ingredient, semaglutide, is also used in the Wegovy injection. Yale Medicine says the semaglutide-based pill must be taken on an empty stomach.
Results, costs and side effects
Participants taking 17.2 milligrams of Foundayo lost around 12% of their body weight on average over 72 weeks. The figure was 15% to 20% for people taking Eli Lilly’s injectable GLP-1 drugs.
Most Foundayo patients begin at the lowest dose and increase through six levels. Jennifer Lake, an assistant professor at the University of Toronto’s Leslie Dan Faculty of Pharmacy, said weight loss may take longer to appear with pills.
Lake said patients are expected to reach the third level, 6 milligrams, before seeing weight loss. That can mean about three months of treatment.
Insurance coverage also affects patients’ choices, Gerstein said. For uninsured patients in Canada, Zepbound can cost $275 to $650 per month, according to digital health platform Felix.
In the United States, Foundayo has a list price of US$650 for a 30-day supply without an insurance plan.
Common side effects of both oral and injectable GLP-1 drugs include nausea and vomiting. Eli Lilly warns against using Foundayo if a patient or family member has a history of thyroid cancer.
Lake advised patients not to stop their medication without consulting a health professional.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say
Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)




















